RU2006141276A - Производное пурина - Google Patents
Производное пурина Download PDFInfo
- Publication number
- RU2006141276A RU2006141276A RU2006141276/04A RU2006141276A RU2006141276A RU 2006141276 A RU2006141276 A RU 2006141276A RU 2006141276/04 A RU2006141276/04 A RU 2006141276/04A RU 2006141276 A RU2006141276 A RU 2006141276A RU 2006141276 A RU2006141276 A RU 2006141276A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutically acceptable
- formula
- acceptable salt
- solvate
- ethyl
- Prior art date
Links
- UYXBDOYZQOVQDV-PZUBYWIQSA-N CC[n]1nnc([C@H](CC2)OCC2c2nc(NCCc3c[n](C)cn3)nc(NC(CC3)CCC3Nc3nc(NCCc4c[n](C)cn4)nc4c3nc[n]4SC(C(C3C=O)=O)O/C3=C\c3n[n](CC)nn3)c2/N=C\C)n1 Chemical compound CC[n]1nnc([C@H](CC2)OCC2c2nc(NCCc3c[n](C)cn3)nc(NC(CC3)CCC3Nc3nc(NCCc4c[n](C)cn4)nc4c3nc[n]4SC(C(C3C=O)=O)O/C3=C\c3n[n](CC)nn3)c2/N=C\C)n1 UYXBDOYZQOVQDV-PZUBYWIQSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Claims (8)
2. (2R,3R,4S,5R,2'R,3'R,4'S,5'R)-2,2'-{транс-1,4-Циклогександиилбис[имино(2-{[2-(1-метил-1H-имидазол-4-ил)этил]амино}-9H-пурин-6,9-диил)]}бис[5-(2-этил-2H-тетразол-5-ил)тетрагидро-3,4-фурандиол] в форме фармацевтически приемлемой соли.
3. Фармацевтическая композиция, содержащая соединение по п.1 или 2 или его фармацевтически приемлемые соль или сольват, возможно, с одним или более чем одним фармацевтически приемлемым разбавителем или носителем.
4. Соединение по п.1 или 2 или его фармацевтически приемлемые соль или сольват для применения в терапии.
5. Соединение по п.1 или 2 или его фармацевтически приемлемые соль или сольват для применения в лечении воспалительных заболеваний.
6. Применение соединения по п.1 или 2 или его фармацевтически приемлемых соли или сольвата в производстве лекарства для лечения воспалительных заболеваний.
7. Способ лечения или профилактики воспалительных заболеваний, включающий введение пациенту эффективного количества соединения формулы (I) по п.1 или 2 или его фармацевтически приемлемых соли или сольвата.
8. Способ получения соединения формулы (I) по п.1, включающий:
а) взаимодействие соединения формулы (II)
где L представляет собой уходящую группу, или его защищенного производного с [2-(1-метил-1H-имидазол-4-ил)этил]амином; либо
б) взаимодействие соединения формулы (V)
с соединением формулы (IV)
или его защищенным производным; либо
в) удаление защиты с защищенного производного соединения формулы (I).
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0411563.0 | 2004-05-24 | ||
GB0411563A GB0411563D0 (en) | 2004-05-24 | 2004-05-24 | Compounds |
GB0509521.1 | 2005-05-10 | ||
GB0509521A GB0509521D0 (en) | 2005-05-10 | 2005-05-10 | Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2006141276A true RU2006141276A (ru) | 2008-06-27 |
Family
ID=34968031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006141276/04A RU2006141276A (ru) | 2004-05-24 | 2005-05-23 | Производное пурина |
Country Status (16)
Country | Link |
---|---|
US (1) | US7737126B2 (ru) |
EP (1) | EP1756120B1 (ru) |
JP (1) | JP5007225B2 (ru) |
AR (1) | AR049384A1 (ru) |
AT (1) | ATE556080T1 (ru) |
AU (1) | AU2005247601A1 (ru) |
BR (1) | BRPI0511424A (ru) |
CA (1) | CA2566863A1 (ru) |
ES (1) | ES2383604T3 (ru) |
IL (1) | IL179009A0 (ru) |
MA (1) | MA28611B1 (ru) |
MX (1) | MXPA06013627A (ru) |
NO (1) | NO20065757L (ru) |
PE (1) | PE20060272A1 (ru) |
RU (1) | RU2006141276A (ru) |
WO (1) | WO2005116037A1 (ru) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GT200500281A (es) * | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0500785D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
GB0514809D0 (en) * | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
GB0523778D0 (en) * | 2005-11-23 | 2006-01-04 | Glaxo Group Ltd | Novel method |
GB0523845D0 (en) * | 2005-11-23 | 2006-01-04 | Glaxo Group Ltd | Novel salts |
US20090163723A1 (en) * | 2005-11-25 | 2009-06-25 | Hideki Kimura | Method for producing sulfonium fluorinated alkylfluorophosphate |
PE20071068A1 (es) | 2005-12-20 | 2007-12-13 | Glaxo Group Ltd | Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3 |
GB0607950D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
US8258141B2 (en) | 2006-04-21 | 2012-09-04 | Novartis Ag | Organic compounds |
GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
EP1889846A1 (en) * | 2006-07-13 | 2008-02-20 | Novartis AG | Purine derivatives as A2a agonists |
EP1903044A1 (en) * | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
KR20090087054A (ko) * | 2006-11-10 | 2009-08-14 | 노파르티스 아게 | 시클로펜텐 디올 모노아세테이트 유도체 |
Family Cites Families (204)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE768925A (fr) | 1970-06-30 | 1971-11-03 | Takeda Chemical Industries Ltd | Derives d'adenosine et procede de preparation |
DE2034785A1 (de) | 1970-07-14 | 1972-01-20 | Boehnnger Mannheim GmbH, 6800 Mann heim Waldhof | Adenosin 5 carbonsäurederivate |
CA1019727A (en) | 1971-03-18 | 1977-10-25 | Abbott Laboratories | Adenosine-5'-carboxylic acid amides |
BE789773A (fr) * | 1971-10-08 | 1973-04-06 | Schering Ag | Adenosines n6 -substituees et leur procede de |
US3864483A (en) * | 1972-03-22 | 1975-02-04 | Abbott Lab | Adenosine-5{40 -carboxylic acid amides |
CA1082695A (en) | 1972-04-10 | 1980-07-29 | Francis E. Fischer | Process for preparing adenosine-5'-carboxamides |
US3966917A (en) * | 1974-07-30 | 1976-06-29 | Abbott Laboratories | Platelet aggregation inhibitors |
DE2621470A1 (de) | 1976-05-14 | 1977-12-01 | Pharma Waldhof Gmbh & Co | Nucleosidcarbonsaeurenitrile und ihre derivate, und verfahren zu ihrer herstellung |
US4167565A (en) * | 1976-11-08 | 1979-09-11 | Abbott Laboratories | Adenosine-5'-carboxamides and method of use |
AU8379182A (en) | 1981-06-04 | 1982-12-09 | Procter & Gamble Company, The | Composition of salicylates and purine derivatives |
CA1239397A (en) | 1983-08-01 | 1988-07-19 | James A. Bristol | N.sup.6-substituted adenosines |
DE3406533A1 (de) * | 1984-02-23 | 1985-08-29 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten |
JPH0655756B2 (ja) * | 1984-04-18 | 1994-07-27 | ネルソン・リサ−チ・アンド・デベロツプメント・カンパニ− | 心臓血管拡張薬としてのn−6置換アデノシン誘導体 |
US5310731A (en) | 1984-06-28 | 1994-05-10 | Whitby Research, Inc. | N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents |
CA1254888A (en) | 1984-10-26 | 1989-05-30 | Bharat Trivedi | N.sup.6-bicycloadenosines |
AU575438B2 (en) | 1984-10-26 | 1988-07-28 | Warner-Lambert Company | N6 - substituted deoxyribose analogues of adenosines |
US4663313A (en) * | 1984-10-26 | 1987-05-05 | Warner-Lambert Company | N6 -tricyclic adenosines for treating hypertension |
US4738954A (en) | 1985-11-06 | 1988-04-19 | Warner-Lambert Company | Novel N6 -substituted-5'-oxidized adenosine analogs |
US4755594A (en) | 1986-01-31 | 1988-07-05 | Warner-Lambert Company | N6 -substituted adenosines |
US5106837A (en) * | 1988-03-16 | 1992-04-21 | The Scripps Research Institute | Adenosine derivatives with therapeutic activity |
JPH0696534B2 (ja) * | 1986-04-25 | 1994-11-30 | ヘキストジヤパン株式会社 | 抗痴呆剤 |
US4767747A (en) * | 1986-08-28 | 1988-08-30 | Warner-Lambert Company | Method for treating congestive heart failure with N6 -acenaphthyl adenosine |
AU8276187A (en) | 1986-10-31 | 1988-05-25 | Warner-Lambert Company | Selected n6-substituted adenosines having selective a2 binding activity |
AU8274187A (en) | 1986-10-31 | 1988-05-25 | Warner-Lambert Company | Heteroaromatic derivatives of adenosine |
NL8702926A (nl) | 1986-12-15 | 1988-07-01 | Sandoz Ag | Nieuwe furanuronzuurderivaten en werkwijzen voor het bereiden en toepassen van deze derivaten. |
EP0277917A3 (en) | 1987-02-04 | 1990-03-28 | Ciba-Geigy Ag | Certain adenosine 5'-carboxamide derivatives |
US4968697A (en) * | 1987-02-04 | 1990-11-06 | Ciba-Geigy Corporation | 2-substituted adenosine 5'-carboxamides as antihypertensive agents |
US4962194A (en) * | 1987-04-02 | 1990-10-09 | Warner-Lambert Company | Method of preparing 51,N6-disubstituted adenosines from inosines |
LU87181A1 (fr) | 1987-04-06 | 1988-11-17 | Sandoz Sa | Nouveaux derives de l'acide furannuronique,leur preparation et leur utilisation comme medicaments |
US5219840A (en) * | 1987-04-06 | 1993-06-15 | Sandoz Ltd. | Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives |
JPH0725785B2 (ja) * | 1989-01-11 | 1995-03-22 | 日本臓器製薬株式会社 | アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物 |
US5646128A (en) * | 1989-09-15 | 1997-07-08 | Gensia, Inc. | Methods for treating adenosine kinase related conditions |
IE903747A1 (en) | 1989-10-19 | 1991-04-24 | Searle & Co | Method of treating gastrointestinal motility disorders |
US5055569A (en) | 1989-10-19 | 1991-10-08 | G. D. Searle & Co. | N-(6)-substituted adenosine compounds |
ATE271064T1 (de) | 1990-01-11 | 2004-07-15 | Isis Pharmaceuticals Inc | Oligonukleotidderivate zur detektieren und modulation von rna aktivität und genexpression |
US5140015A (en) | 1990-02-20 | 1992-08-18 | Whitby Research, Inc. | 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents |
GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
US5280015A (en) * | 1990-09-05 | 1994-01-18 | The United States Of America As Represented By The Department Of Health And Human Services | 2-substituted adenosines and 2-substituted adenosine 5'-carboxamides |
DE69123974T2 (de) | 1990-09-25 | 1997-05-07 | Rhone Poulenc Rorer Int | Verbindungen welche antihypertensive und antiischemische eigenschaften besitzen |
CA2100863A1 (en) | 1991-01-23 | 1992-07-24 | David A. Bullough | Adenosine kinase inhibitors |
GB9127376D0 (en) | 1991-12-24 | 1992-02-19 | Wellcome Found | Amidino derivatives |
FR2685918B1 (fr) | 1992-01-08 | 1995-06-23 | Union Pharma Scient Appl | Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant. |
FR2687678B1 (fr) * | 1992-01-31 | 1995-03-31 | Union Pharma Scient Appl | Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant. |
EP0633776B1 (en) | 1992-04-02 | 2001-05-09 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
US5424297A (en) * | 1992-04-27 | 1995-06-13 | University Of Virginia Alumni Patents Foundation | Adenosine dextran conjugates |
AU4772493A (en) | 1992-07-15 | 1994-02-14 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Sulfo-derivatives of adenosine |
GB9301000D0 (en) | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
WO1994018215A1 (en) | 1993-02-03 | 1994-08-18 | Gensia, Inc. | Adenosine kinase inhibitors comprising lyxofuranosyl derivatives |
IL108523A0 (en) | 1993-02-03 | 1994-05-30 | Gensia Inc | Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain |
AU7331094A (en) | 1993-07-13 | 1995-02-13 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The | A3 adenosine receptor agonists |
US5446046A (en) | 1993-10-28 | 1995-08-29 | University Of Florida Research Foundation | A1 adenosine receptor agonists and antagonists as diuretics |
WO1995018817A1 (fr) | 1994-01-07 | 1995-07-13 | Laboratoires Upsa | Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant |
ATE229001T1 (de) | 1994-06-15 | 2002-12-15 | Wellcome Found | Zwischenprodukte verwendbar in der herstellung von enzym-inhibitoren |
GB9414193D0 (en) | 1994-07-14 | 1994-08-31 | Glaxo Group Ltd | Compounds |
GB9414208D0 (en) | 1994-07-14 | 1994-08-31 | Glaxo Group Ltd | Compounds |
WO1996036729A1 (en) * | 1995-05-18 | 1996-11-21 | Coulter International Corp. | An assay reagent and a method of making and using the assay reagent |
US6403599B1 (en) | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
US5789589A (en) | 1996-04-22 | 1998-08-04 | Drug Innovation & Design, Inc. | Guanine analog phosphates |
AU3255097A (en) | 1996-07-05 | 1998-02-02 | Novo Nordisk A/S | Novel (n)-alkoxyadenine derivatives acting as cytokine inhibitors |
UA51716C2 (ru) | 1996-07-08 | 2002-12-16 | Авентіс Фармасьютікалз Продактс Інк. | СОЕДИНЕНИЯ, ИМЕЮЩИЕ ГИПОТЕНЗИВНОЕ, КАРДИОПРОТЕКТОРНОЕ, АНТИ-ИШЕМИЧЕСКОЕ И АНТИЛИПОЛИТИЧЕСКОЕ СВОЙСТВА, фармацевтическая композиция и способЫ лечения |
AU4377397A (en) | 1996-10-14 | 1998-05-11 | Novo Nordisk A/S | Novel therapeutically active adenosine derivatives |
TW528755B (en) * | 1996-12-24 | 2003-04-21 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
WO1998030900A2 (en) * | 1997-01-06 | 1998-07-16 | Klaus Trier Aps | Screening method for compounds active in treating myopia and hypermetropia |
MY117948A (en) | 1997-01-13 | 2004-08-30 | Glaxo Group Ltd | Nitride oxide synthase inhibitors. |
DE19723722A1 (de) | 1997-05-30 | 1998-12-10 | Schering Ag | Nichtsteroidale Gestagene |
WO1999016766A1 (fr) | 1997-10-01 | 1999-04-08 | Kyowa Hakko Kogyo Co., Ltd. | Derives de benzodioxole |
YU44900A (sh) | 1998-01-31 | 2003-01-31 | Glaxo Group Limited | Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola |
US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
CO4990969A1 (es) | 1998-02-14 | 2000-12-26 | Glaxo Group Ltd | Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol |
PT1070056E (pt) | 1998-03-14 | 2004-11-30 | Altana Pharma Ag | Inibidores de pde iii/iv a base de ftalazinona |
GB9811599D0 (en) | 1998-05-30 | 1998-07-29 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
GB9813565D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
GB9813540D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
ATE246701T1 (de) | 1998-06-23 | 2003-08-15 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivate |
MY121142A (en) | 1999-02-23 | 2005-12-30 | Smithkline Beecham Corp | Controlled release formulation for treating copd |
EP1175422A2 (en) | 1999-05-04 | 2002-01-30 | Ligand Pharmaceuticals Incorporated | Tetracyclic progesterone receptor modulator compounds and methods |
ATE303387T1 (de) * | 1999-07-02 | 2005-09-15 | Eisai Co Ltd | Kondensierte imidazolderivate und arzneimittel gegen diabetes mellitus |
ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
US6263209B1 (en) | 1999-07-28 | 2001-07-17 | Motorola, Inc. | Method and apparatus in a wireless communication system for creating a learning function |
CO5180649A1 (es) | 1999-09-01 | 2002-07-30 | Abbott Lab | Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes |
US6803457B1 (en) * | 1999-09-30 | 2004-10-12 | Pfizer, Inc. | Compounds for the treatment of ischemia |
OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
SK10342002A3 (sk) | 2000-01-31 | 2003-12-02 | Pfizer Products Inc. | Pyrimidínkarboxamidy užitočné ako selektívne inhibítory izozymov PDE4 |
EE200200425A (et) | 2000-01-31 | 2003-10-15 | Pfizer Products Inc. | Selektiivsete PDE4 isosüümide inhibiitoritena kasulikud nikotiinamiidi bensokondenseerunud heterotsüklüülderivaadid |
US7585847B2 (en) * | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
US6710086B1 (en) * | 2000-02-25 | 2004-03-23 | Medinox, Inc. | Protected forms of pharmacologically active agents and uses therefor |
US6753322B2 (en) * | 2000-06-06 | 2004-06-22 | Pfizer Inc | 2-aminocarbonyl-9H-purine derivatives |
US6921753B2 (en) * | 2000-06-27 | 2005-07-26 | Pfizer Inc | Purine derivatives |
GB0015727D0 (en) | 2000-06-27 | 2000-08-16 | Pfizer Ltd | Purine derivatives |
GB0016002D0 (en) | 2000-06-29 | 2000-08-23 | Glaxo Group Ltd | Novel process for preparing crystalline particles |
CN1678594A (zh) | 2000-09-29 | 2005-10-05 | 葛兰素集团有限公司 | 用于治疗炎性疾病的吗啉-乙酰胺衍生物 |
AU2002210761A1 (en) | 2000-11-03 | 2002-05-15 | Glaxo Group Limited | Method of determining susceptibility to diseases |
GB0028383D0 (en) * | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
GB0031179D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
DE10064997A1 (de) * | 2000-12-23 | 2002-06-27 | Merck Patent Gmbh | Benzoylpyridazine |
US6484903B2 (en) | 2001-01-09 | 2002-11-26 | Riverwood International Corporation | Carton with an improved dispensing feature in combination with a unique handle |
IL156704A0 (en) | 2001-01-16 | 2004-01-04 | Can Fite Biopharma Ltd | Use of an adenosine a3 receptor agonist for inhibition of viral replication |
US7250518B2 (en) * | 2001-01-31 | 2007-07-31 | Pfizer Inc. | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes |
ATE293109T1 (de) | 2001-01-31 | 2005-04-15 | Pfizer Prod Inc | Nikotinsäureamid-derivate und ihre mimetika als inhibitoren von pde4-isozyms |
GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
GB0104555D0 (en) | 2001-02-23 | 2001-04-11 | Glaxo Group Ltd | New Therapeutic method |
GB2372742A (en) * | 2001-03-03 | 2002-09-04 | Univ Leiden | C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses |
US7144908B2 (en) | 2001-03-08 | 2006-12-05 | Glaxo Group Limited | Agonists of beta-adrenoceptors |
WO2002072067A2 (en) | 2001-03-12 | 2002-09-19 | Glaxo Group Limited | Pharmaceutical aerosol formulation |
EP1370521B1 (en) | 2001-03-22 | 2007-12-19 | Glaxo Group Limited | Formanilide derivatives as beta2-adrenoreceptor agonists |
GEP20053675B (en) | 2001-03-30 | 2005-11-25 | Pfizer Prod Inc | Pyridazinone Aldose Reductase Inhibitors |
US20040204481A1 (en) * | 2001-04-12 | 2004-10-14 | Pnina Fishman | Activation of natural killer cells by adenosine A3 receptor agonists |
US6903109B2 (en) * | 2001-04-18 | 2005-06-07 | Ortho-Muniel Pharmaceutical, Inc. | Arylindenopyridines and related therapeutic and prophylactic methods |
GB0120124D0 (en) * | 2001-05-04 | 2001-10-10 | Aventis Pharm Prod Inc | Effect of timing and duration of administration of amp 579 on reperfusion injury in rabbit heart |
US20030013675A1 (en) | 2001-05-25 | 2003-01-16 | Boehringer Ingelheim Pharma Kg | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases |
BR0209986A (pt) | 2001-05-25 | 2004-04-06 | Pfizer | Agonista de a2a em combinação com um agente anticolinérgico, para o tratamento de doenças obstrutivas das vias respiratórias |
US20030078232A1 (en) | 2001-08-08 | 2003-04-24 | Elfatih Elzein | Adenosine receptor A3 agonists |
US7262176B2 (en) * | 2001-08-08 | 2007-08-28 | Cv Therapeutics, Inc. | Adenosine A3 receptor agonists |
MXPA04002405A (es) | 2001-09-14 | 2004-05-31 | Glaxo Group Limetd | Derivados de fenetanolamina para tratamiento de enfermedades respiratorias. |
WO2003029264A2 (en) | 2001-10-01 | 2003-04-10 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof |
HUP0401984A3 (en) * | 2001-10-31 | 2005-06-28 | Merck Patent Gmbh | Use of type 4 phosphodiesterase inhibitors for preparation of pharmaceutical compositions and combination with other active ingredients |
JP2005511590A (ja) * | 2001-11-02 | 2005-04-28 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | アデノシンa1/a2アゴニストおよびナトリウム水素交換体阻害剤を含む医薬組成物 |
ATE335486T1 (de) * | 2001-11-05 | 2006-09-15 | Merck Patent Gmbh | Hydrazono-malonitrile |
WO2003042160A1 (en) | 2001-11-13 | 2003-05-22 | Theravance, Inc. | Aryl aniline beta-2 adrenergic receptor agonists |
US6911453B2 (en) * | 2001-12-05 | 2005-06-28 | Aventis Pharma Deutschland Gmbh | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them |
GB0129273D0 (en) * | 2001-12-06 | 2002-01-23 | Pfizer Ltd | Crystalline drug form |
US6703405B2 (en) * | 2001-12-22 | 2004-03-09 | Aventis Pharma Deutschland Gmbh | Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as a medicament, and medicament containing them |
DE10163991A1 (de) * | 2001-12-24 | 2003-07-03 | Merck Patent Gmbh | Pyrrolo-pyrimidine |
ES2276038T3 (es) | 2002-01-14 | 2007-06-16 | Boehringer Ingelheim Pharmaceuticals Inc. | Mimeticos de glucocorticoides, metodos para su obtencion, formulaciones farmaceuticas que los contienen y usos de los mismos. |
WO2003062256A1 (en) | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents |
AU2003214879B2 (en) | 2002-01-22 | 2008-02-07 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
CA2474337A1 (en) | 2002-01-25 | 2003-07-31 | Muscagen Limited | Compounds useful as a3 adenosine receptor agonists |
US6756392B2 (en) * | 2002-02-11 | 2004-06-29 | Pfizer Inc | Nicotinamide derivatives useful as PDE4 inhibitors |
ATE378049T1 (de) * | 2002-02-11 | 2007-11-15 | Pfizer | Nicotinamid-derivate als pde4-hemmer |
GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
EP1486204A1 (en) | 2002-03-18 | 2004-12-15 | Yamanouchi Pharmaceutical Co. Ltd. | Powdery medicinal compositions for inhalation and process for producing the same |
US20040053953A1 (en) * | 2002-03-18 | 2004-03-18 | Schering Corporation | Treatment of chemokine mediated diseases |
GB0206657D0 (en) | 2002-03-21 | 2002-05-01 | Glaxo Group Ltd | Novel intermediate and process |
GB0206655D0 (en) | 2002-03-21 | 2002-05-01 | Glaxo Group Ltd | Novel process |
EP1490317A1 (en) | 2002-03-26 | 2004-12-29 | Boehringer Ingelheim Pharmaceuticals Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
UA80120C2 (en) | 2002-03-26 | 2007-08-27 | Boehringer Ingelheim Pharma | Glucocorticoid mimetics, pharmaceutical composition based thereon |
DE10215316C1 (de) | 2002-04-02 | 2003-12-18 | Schering Ag | Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer |
EP1496892B1 (en) | 2002-04-11 | 2011-01-26 | Merck Sharp & Dohme Corp. | 1h-benzo(f)indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
GB0208608D0 (en) | 2002-04-13 | 2002-05-22 | Glaxo Group Ltd | Composition |
US20040127510A1 (en) * | 2002-04-16 | 2004-07-01 | Heintzelman Geoffrey R. | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods |
DE60318193T2 (de) | 2002-04-25 | 2008-12-04 | Glaxo Group Ltd., Greenford | Phenethanolaminderivate |
AU2003251303A1 (en) | 2002-05-21 | 2003-12-12 | Glaxo Group Limited | Pharmaceutical products and methods of manufacture |
US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
BR0312575A (pt) | 2002-07-08 | 2005-05-03 | Pfizer Prod Inc | Moduladores do receptor de glicocorticóides |
WO2004009017A2 (en) | 2002-07-18 | 2004-01-29 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
ES2337679T3 (es) | 2002-07-18 | 2010-04-28 | Bristol-Myers Squibb Company | Composiciones y procedimientos que implican el sitio ii de los receptores nucleares de hormonas. |
GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
WO2004018429A2 (en) | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US20050113302A1 (en) | 2002-08-29 | 2005-05-26 | Thompson John F. | A3 receptor-mediated cardioprotective proteins and therapeutic and diagnostic methods of use |
GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
WO2004022573A2 (en) | 2002-09-09 | 2004-03-18 | Cv Therapeutics, Inc. | Adenosine a3 receptor agonists |
SI1400245T1 (sl) | 2002-09-09 | 2006-10-31 | Trigen Ltd | Soli boronske kisline, uporabne v parenteralnih formulacijah za selektivno inhibiranje trombina |
US20050288253A1 (en) * | 2002-09-09 | 2005-12-29 | Trigen Limited | Boronic acid salts |
CA2499014A1 (en) | 2002-09-16 | 2004-03-25 | Agennix Incorporated | Lactoferrin compositions and methods of wound treatment |
KR20050052501A (ko) | 2002-09-16 | 2005-06-02 | 글락소 그룹 리미티드 | 피라졸로[3,4-b]피리딘 화합물, 및 포스포디에스테라아제억제제로서의 이들의 용도 |
EP1542996A4 (en) | 2002-09-20 | 2009-11-18 | Merck & Co Inc | OCTAHYDRO-2H-NAPHTOc1,2-F INDOL-4-CARBONSUUREAMIDE DERIVATIVES AS SELECTIVE MODULATORS OF THE GLUCOCORTICOID RECEPTOR |
US20040229780A1 (en) * | 2002-09-20 | 2004-11-18 | Olivera Baldomero M. | KappaM-conopeptides as organ protectants |
AU2003270752A1 (en) | 2002-09-27 | 2004-04-19 | King Pharmaceuticals Research And Development, Inc. | A method to demonstrate the efficacy of pharmacological stress agent |
WO2004030621A2 (en) | 2002-09-30 | 2004-04-15 | The Trustees Of Boston University | Method of treating cancer using adenosine and its analogs |
MXPA05003867A (es) * | 2002-10-09 | 2005-11-23 | Schering Corp | Tiadiazoldioxidos y tiadiazoloxidos como ligandos de receptor cxc-y cc-quimiocina. |
US6844362B2 (en) * | 2002-10-11 | 2005-01-18 | Pfizer Inc | Indole derivatives useful for the treatment of diseases |
EP1407769A1 (en) | 2002-10-11 | 2004-04-14 | Pfizer Limited | Indole derivatives as beta-2 agonists |
WO2004032921A1 (en) | 2002-10-11 | 2004-04-22 | Pfizer Limited | Indole derivatives as beta-2 agonists |
WO2004037807A2 (en) | 2002-10-22 | 2004-05-06 | Glaxo Group Limited | Medicinal arylethanolamine compounds |
EP1578758A4 (en) | 2002-10-25 | 2009-09-30 | Us Gov Health & Human Serv | PURE NUCLEOSIDES |
GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
ES2302956T3 (es) | 2002-10-28 | 2008-08-01 | Glaxo Group Limited | Derivado de fenetanolamina para el tratamiento de enfermedades respiratorias. |
GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
WO2004050040A2 (en) | 2002-12-03 | 2004-06-17 | Vela Pharmaceuticals, Inc. | Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5h-2,3-benzodiazepine and uses thereof |
GB0228723D0 (en) | 2002-12-09 | 2003-01-15 | Cambridge Biotechnology Ltd | Treatment of pain |
CA2451267A1 (en) | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
JP2006515367A (ja) | 2003-01-14 | 2006-05-25 | アルタナ ファルマ アクチエンゲゼルシャフト | リンパ系細胞腫瘍の治療のためのpde4阻害剤 |
US20040166574A1 (en) | 2003-02-25 | 2004-08-26 | Antonius John I. | Microorganism |
US20040175382A1 (en) * | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
GB0305153D0 (en) | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Identification of therapeutic compounds |
GB0305149D0 (en) | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Compounds for the treatment of pain |
GB0305150D0 (en) | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Use of therapeutic compounds |
EP1460064A1 (en) | 2003-03-14 | 2004-09-22 | Pfizer Limited | Indole-2-carboxamide derivatives useful as beta-2 agonists |
US20040184995A1 (en) * | 2003-03-17 | 2004-09-23 | Yamanouchi Pharmaceutical Co., Ltd. | Novel dry powder inhalation for lung-delivery and manufacturing method thereof |
US20040258740A1 (en) * | 2003-04-10 | 2004-12-23 | Nene Labs | Transdermal delivery composition |
CA2522666A1 (en) | 2003-04-18 | 2004-10-28 | Pharmacia & Upjohn Company Llc | Combination therapies for chronic obstructive pulmonary disease (copd) |
EP1477167A1 (en) | 2003-05-15 | 2004-11-17 | Pfizer Limited | [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists |
US7268147B2 (en) * | 2003-05-15 | 2007-09-11 | Pfizer Inc | Compounds useful for the treatment of diseases |
TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
GB0312832D0 (en) | 2003-06-04 | 2003-07-09 | Pfizer Ltd | 2-amino-pyridine derivatives useful for the treatment of diseases |
EP1633714B1 (en) | 2003-06-04 | 2008-01-23 | Pfizer Limited | 2-amino-pyridine derivatives as beta-2 adrenoreceptor agonists |
US7375100B2 (en) * | 2003-06-04 | 2008-05-20 | Pfizer Inc | 2-amino-pyridine derivatives useful for the treatment of diseases |
US7067541B2 (en) * | 2003-06-04 | 2006-06-27 | Pfizer Inc | 2-amino-pyridine derivatives useful for the treatment of diseases |
WO2004110454A1 (ja) | 2003-06-13 | 2004-12-23 | Ishihara Sangyo Kaisha, Ltd. | アデノシンA2a受容体アゴニストの投与が必要な疾患を治療又は予防するための組成物 |
US6974862B2 (en) | 2003-06-20 | 2005-12-13 | Kensey Nash Corporation | High density fibrous polymers suitable for implant |
GB0317516D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as PDE4 inhibitors |
US20050020587A1 (en) * | 2003-07-25 | 2005-01-27 | Pfizer Inc | Nicotinamide derivatives useful as PDE4 inhibitors |
US7153870B2 (en) * | 2003-07-25 | 2006-12-26 | Pfizer Inc. | Nicotinamide derivatives useful as PDE4 inhibitors |
GB0317498D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Compounds |
GB0317471D0 (en) | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Novel compounds |
GB0317509D0 (en) | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as PDE4 inhibitors |
GB0317484D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
GB0317482D0 (en) | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
US7132435B2 (en) * | 2003-07-25 | 2006-11-07 | Pfizer Inc. | Compounds |
GB0317472D0 (en) | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as PDE4 inhibitors |
GB0317951D0 (en) | 2003-07-31 | 2003-09-03 | Trigen Ltd | Compounds |
NZ545979A (en) | 2003-09-18 | 2009-02-28 | King Pharmaceuticals Res & Dev | Novel adenosine A3 receptor agonists |
-
2005
- 2005-05-20 PE PE2005000560A patent/PE20060272A1/es not_active Application Discontinuation
- 2005-05-20 AR ARP050102092A patent/AR049384A1/es unknown
- 2005-05-23 MX MXPA06013627A patent/MXPA06013627A/es not_active Application Discontinuation
- 2005-05-23 AU AU2005247601A patent/AU2005247601A1/en not_active Abandoned
- 2005-05-23 AT AT05743186T patent/ATE556080T1/de active
- 2005-05-23 EP EP05743186A patent/EP1756120B1/en active Active
- 2005-05-23 BR BRPI0511424-1A patent/BRPI0511424A/pt not_active Application Discontinuation
- 2005-05-23 CA CA002566863A patent/CA2566863A1/en not_active Abandoned
- 2005-05-23 ES ES05743186T patent/ES2383604T3/es active Active
- 2005-05-23 JP JP2007517114A patent/JP5007225B2/ja not_active Expired - Fee Related
- 2005-05-23 RU RU2006141276/04A patent/RU2006141276A/ru unknown
- 2005-05-23 US US11/569,406 patent/US7737126B2/en not_active Expired - Fee Related
- 2005-05-23 WO PCT/EP2005/005651 patent/WO2005116037A1/en active Application Filing
-
2006
- 2006-11-02 IL IL179009A patent/IL179009A0/en unknown
- 2006-11-28 MA MA29493A patent/MA28611B1/fr unknown
- 2006-12-13 NO NO20065757A patent/NO20065757L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AR049384A1 (es) | 2006-07-26 |
JP2008500378A (ja) | 2008-01-10 |
AU2005247601A1 (en) | 2005-12-08 |
PE20060272A1 (es) | 2006-05-22 |
MA28611B1 (fr) | 2007-05-02 |
NO20065757L (no) | 2006-12-13 |
ATE556080T1 (de) | 2012-05-15 |
ES2383604T3 (es) | 2012-06-22 |
WO2005116037A1 (en) | 2005-12-08 |
BRPI0511424A (pt) | 2007-12-11 |
US20080132526A1 (en) | 2008-06-05 |
EP1756120A1 (en) | 2007-02-28 |
US7737126B2 (en) | 2010-06-15 |
EP1756120B1 (en) | 2012-05-02 |
CA2566863A1 (en) | 2005-12-08 |
MXPA06013627A (es) | 2007-02-28 |
IL179009A0 (en) | 2007-03-08 |
JP5007225B2 (ja) | 2012-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2006141276A (ru) | Производное пурина | |
JP2008500378A5 (ru) | ||
RU2470016C2 (ru) | Производное бипиразола | |
RU2401658C2 (ru) | Гетероциклические ингибиторы аспартилпротеазы | |
AU2023204318A1 (en) | Combination therapy for cancer treatment | |
RU2006116887A (ru) | Производные n-[гетероарил(пиперидин-2-ил)метил]бензамида, способ получения указанных соединений и их применение в терапии | |
JP2011511840A5 (ru) | ||
EA200602130A1 (ru) | Замещенные арилацилтиомочевины и родственные соединения; ингибиторы репликации вирусов | |
EA200601846A1 (ru) | Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей | |
JP2005506352A5 (ru) | ||
RU2008129723A (ru) | Ингибиторы ccr9 активности | |
RU2010107284A (ru) | Производные нафтиридина в качестве модуляторов калиевых каналов | |
RU2009114167A (ru) | Комбинации специфических ингибиторов гистоновых деацетилаз класса i с ингибиторами протеасом | |
RU2008142834A (ru) | Модуляция церамидкиназы | |
JP2008531604A5 (ru) | ||
RU2015117267A (ru) | Замещенные соединения амида | |
RU2003132687A (ru) | Лечение диабета типа 2 ингибиторами дипептидилпептидазы iv | |
RU2011117927A (ru) | Карбаматное соединение или его соль | |
RU2011111117A (ru) | Лечение аутоиммунных заболеваний | |
RU2011153353A (ru) | Кетолидные соединения, обладающие противомикробной активностью | |
WO2005095345A3 (en) | Heteroaryl guanidines as inhibitors of viral replication | |
WO2011088126A2 (en) | Treatment of viral infection with prenyltransferase inhibitors | |
RU2008112181A (ru) | Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3 | |
JP2012520321A5 (ru) | ||
RU2002130247A (ru) | Производные оксадиазола, обладающие противоопухолевым действием |